Cargando…
Utility of F-18 FDG PET/CT for Detection of Bone Marrow Metastases in Prostate Cancer Patients Treated with Radium-223
A 76-year-old man with symptomatic bone metastases from castration-resistant prostate cancer underwent Radium-223-dichloride (Ra-223) therapy. Before Ra-223 therapy, he had normal peripheral blood cell counts. Ra-223 therapy relieved his shoulder and low back pain. The elevation of the serum prostat...
Autores principales: | Maruyama, Kaoru, Utsunomia, Keita, Nakamoto, Takahiro, Kawakita, Shigenari, Murota, Takashi, Tanigawa, Noboru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asia Oceania Journal of Nuclear Medicine & Biology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765335/ https://www.ncbi.nlm.nih.gov/pubmed/29333469 http://dx.doi.org/10.22038/aojnmb.2017.9896 |
Ejemplares similares
-
Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer
por: Cox, Heather, et al.
Publicado: (2015) -
Is interim (18)F-fluoride PET/CT a predictor of outcomes
after radium-223 therapy?
por: Etchebehere, Elba, et al.
Publicado: (2019) -
Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride
por: Lien, Lise Marie E, et al.
Publicado: (2015) -
Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223
por: Bauckneht, Matteo, et al.
Publicado: (2019) -
Radium-223 and concomitant therapies: prospects and prudence
por: Yeku, Oladapo, et al.
Publicado: (2016)